Hippocampus-targeted BDNF gene therapy to rescue cognitive impairments of Alzheimer's disease in multiple mouse models
Top Cited Papers
Open Access
- 1 March 2026
- journal article
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (2) , 101649
Abstract
Brain-derived neurotrophic factor (BDNF) can protect neurons from apoptosis and maintain normal synaptic structures, indicating a significant potential for Alzheimer's disease (AD) treatment. However, the method of in vivo BDNF delivery requires further optimization, and the therapeutic efficacy of BDNF in AD animal models needs to be further evaluated. Here, we demonstrated that a newly engineered adeno-associated virus (AAV) serotype termed AAVT42 showed better tropism for neurons than AAV9 in the central nervous system (CNS). We analyzed the therapeutic potentials of AAVT42-delivered BDNF in three AD mouse models: amyloid precursor protein/presenilin-1 (APP/PS1), rTg4510, and 3 × Tg. Long-term BDNF expression in the hippocampus mitigated neuronal degeneration or loss in these AD mice, and alleviated their cognitive impairment, with no discernible effect on amyloid-β deposition or tau phosphorylation. Furthermore, transcriptomic analysis in 3 × Tg mice revealed that BDNF orchestrated the up-regulation of genes associated with neuronal structural organization and synaptic transmissions, such as Neuropeptide Y (Npy), Corticotropin-releasing hormone (Crh), Tachykinin precursor 1 (Tac1), and the down-regulation of Bone morphogenetic proteins (Bmps). Our study highlighted the efficacy of AAVT42 in gene delivery to CNS and validated the therapeutic benefits of BDNF in treating AD, which will be useful for future translational research on AD treatment using an AAV delivery system.Keywords
Funding Information
- National Natural Science Foundation of China (82471501)
- National Natural Science Foundation of China (82360226)
- National Key Research and Development Program of China (2021YFC2700803)
This publication has 83 references indexed in Scilit:
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Hippocampal BMP signaling as a common pathway for antidepressant actionCellular and Molecular Life Sciences, 2021
- Crossing the blood-brain barrier with AAV vectorsMetabolic Brain Disease, 2020
- Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer DiseaseJAMA Neurology, 2018
- Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling PathwayCellular and Molecular Neurobiology, 2015
- Nerve Growth Factor Gene TherapyJAMA Neurology, 2015
- Directed Evolution of Adeno-Associated Virus (AAV) as Vector for Muscle Gene Therapy2010
- Corticotropin-Releasing Hormone Protects Neurons against Insults Relevant to the Pathogenesis of Alzheimer's DiseaseNeurobiology of Disease, 2001
- The role of microtubule‐associated protein 2 (MAP‐2) in neuronal growth, plasticity, and degenerationJournal of Neuroscience Research, 1992
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991